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Abstract 
Despite the availability of generic antiepileptic drugs (AEDs), still patients and neurologists hesitate to make a switch 
due to assorted reasons. The objectives of this review were to evaluate the risks associated with the generic sub-
stitution of AEDs. In this context, we also summarized the recommendations of various international societies to 
treat epileptic patients. We used a number of electronic databases to identify the relevant published studies which 
demonstrated the potential problems and recommendations regarding generic substitution of AEDs. Of 204 articles 
found initially, 153 were selected for additional review. Subsequently, 68 articles were finally selected. This review con-
cluded that potential problems linked with the generic substitution of AEDs could be bioequivalence issues, failure 
of drug therapy, emergence of adverse events and increase in the frequency of seizures. The reasons could be the 
pharmacokinetics properties of AEDs and unique characteristics of some epilepsy patients. Consequently, the generic 
substitution of AEDs affects the successful treatment and quality of life of the patients. Various guidelines recommend 
the well-controlled epileptic patients to avoid switching from brand-to-generic products, generic-to-brand products 
or generic to some other generic products.
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Background
Epilepsy is a familiar, chronic and critical neurologic dis-
order characterized by episodes (such as seizures) requir-
ing most of the times a lifelong management (Bialer 
and Midha 2010; American Medical Association 2009). 
Being one of the most prevalent diseases, it affects about 
50 million people globally and out of them 40 million are 
from developing countries (World Health Organization 
2001). In low-income countries, its incidence may reach 
at a higher level of 190 in each 100,000 persons (Placen-
cia et  al. 1994). Antiepileptic drugs (AEDs) have gained 
much attention because of the fact that about 70  % of 
the epilepsy patients achieve seizure remission allowing 
them to live a normal life (Heaney and Sander 2007).
Trepidations about the safety and costs of the medi-
cines have intensified the considerations to the clinical 
equivalence and role of the generic medicines. These 
are the products with same active pharmaceutical 
ingredient(s) (qualitatively as well as quantitatively) as 
that of the reference product (Van Paesschen et al. 2009). 
Generic medicines play an important role in patient 
adherence to the therapy because most of the times these 
are available at a considerably low price as compared to 
the branded products (Shrank et al. 2006; Goldman et al. 
2007; Kesselheim et  al. 2006). Reduction in the health-
care expenditures is crucial for economically compro-
mised patients and those with limited health insurance 
facilities.
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United States’ Food and Drug Administration (US 
FDA) states that, in 1984, about 12  % of the prescrip-
tions included generics and this increased to 44  % in 
2000. Regardless of this growth, the increment in the cost 
accounted for only 8 % (Bialer and Midha 2010).
Nevertheless, the major factor attributed to the extensive 
use of generic substituents is the reduced cost, yet low cost 
based generic substitution in epilepsy patients without 
taking into considerations the unique behavior of the dis-
ease is questionable (Jobst and Holmes 2004). Researchers 
have suggested that during the course of epilepsy treat-
ment, generic substitution should either be avoided or 
be done with great precautions (Gidal and Tomson 2008; 
Krämer et al. 2007; Crawford et al. 2006) because it may 
lead to various complications in the patients. The reasons 
accountable to these problems are still not fully explored. 
Consequently, the American Academy of Neurology 
(AAN), various patient organizations and other medical 
associations have argued the generic substitution without 
the physician’s approval (Andermann et al. 2007).
The objectives of the current review were to iden-
tify potential problems arising from the generic 
substitution of AEDs with prime focus on their phar-
macokinetics parameters, desired outcomes and 
recommendations.
Review
Search strategy and selection criteria
We explored databases (PubMed, ScienceDirect, Google 
Scholar, Scopus, Medline, Embase, ProQuest, Springer-
Link, EconLit, etc.) from 1980 to April 2015 with these 
keywords: “generic substitution”, “pharmacokinetics”, 
“bioequivalence”, “bioavailability”, “bioinequivalence” and 
“narrow therapeutic index”, together with generic names 
of antiepileptic drugs in diverse combinations with 
BOOLEAN and MeSH search. Further publications were 
recognized by a manual search of the bibliography and 
reference section of related papers. Of 204 articles found 
initially, 153 were selected for further review. Of 153 arti-
cles, 68 were finally selected (Fig. 1).
Studies from different databases
66 from Google Scholar115 from PubMed, 23 from Other Databases
Total number of studies found initially = 204
Repetition = 51
Not met the criteria = 85
Studies included in final analysis = 68
Others = 12
1. Legislation related = 01
2. Guidelines = 08
3. Editorials, Opinions,              
Letters = 03
Reviews = 15
1. Descriptive reviews = 12
2. Meta-analysis = 03
Studies = 41
1. Uncontrolled studies = 14
2. Surveys = 06
3. Cost analysis = 04
4. Retrospective studies = 06
5. Prospective studies = 11
Fig. 1 Search strategy algorithm
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Results and discussion
Potential problems with the use of generic antiepileptic 
drugs
It is recommended in the several guidelines to monitor 
the serum levels of AEDs in case generic substitution 
is made. This is done to confirm that the drug contact 
stays unaffected (Majkowski et  al. 2004; Krämer et  al. 
2007).
If a dose adjustment is required, it should be done in 
such a way to avoid potential problems as a consequence 
of too low (therapy failure) or too high (adverse effects 
emergence) drug exposure. Preferably, the serum drug 
levels should be monitored both before and after the 
generic substitution of AEDs. However, practically it is 
not possible all the times, and may have cost implica-
tions. Furthermore, the serum drug levels of some newer 
AEDs are inadequately described. Nevertheless, sys-
tematically collected data of serum drug concentrations 
during generic substitution of AEDs offer opportunities 
to evaluate bioequivalence (BE) in routine care settings, 
and to identify the generics with potential risks to the 
patients.
Here, in this review we have summarized some of the 
problems associated with generic substituted older and 
newer AEDs among epileptic patients (Table 1).
Although, the reasons of these potential problems are 
still under-discussion, many researchers have proposed 
different hypothesis regarding the risks arising due to 
the generic substitution of AEDs. Three key aspects sug-
gested by many researchers are; pharmacokinetics char-
acteristics of AEDs, wide-ranging bioequivalence criteria 
and high-risk patient groups.
Pharmacokinetics characteristics of AEDs
The AEDs have numerous pharmacokinetics factors 
that may upsurge the probability of problems associated 
with generic substitution (Table 2) (Crawford et al. 2006; 
Walker and Patsalos 1995; Perucca 1999; Morselli and 
Franco-Morselli 1980; Bauer et al. 1982).
Due to these attributes, it is frequently asked whether 
it is rational to switch the AEDs and pose the patients at 
the risk of adverse clinical condition. For instance, com-
promising potential breakthrough seizures and toxic-
ity associated with the generic substitutions of branded 
Table 1 Potential problems reported with generic substitution of AEDs
AEDs Potential problems References
Carbamazepine Increased breakthrough seizures with generic substitution Sachdeo and Belendiuk (1987), Welty et al. (1992), Koch and Allen 
(1987), Hartley et al. (1991), Berg et al. (2008), Hartley et al. (1990)
Failure of drug therapy with generic substitution Meyer et al. (1992), Welty et al. (1992), Jain (1993)
Toxicity and increased serum levels with generic substitution Gilman et al. (1993), Jumao-as et al. (1989), Reunanen et al. (1992)
Adverse effects with generics Neuvonen (1985), Hartley et al. (1990), Olling et al. (1999), Garnett et al. 
(2005)
Phenytoin Increased breakthrough seizures with generic substitution Yamada and Welty (Yamada and Welty 2011), Berg et al. (2008)
Toxicity and increased serum levels with generic substitution Soryal and Richens (1992)
Adverse effects with generics Chen et al. (1982)
Valproate Increased breakthrough seizures with generic substitution Berg et al. (2008)
Failure of drug therapy Margolese et al. (2010), Sherr and Kelly (1998)
Toxicity and increased serum levels with generic substitution Levine et al. (2000)
Adverse effects with generics Margolese et al. (2010), Sherwood et al. (1998), Wassef et al. (2005), 
Zarate et al. (1999), Schwartz et al. (2000)
Leviteracetam Increased breakthrough seizures with generic substitution Armstrong et al. (2010), Fitzgerald and Jacobson (2011),  
Chaluvadi et al. (2011)
Adverse effects with generics (Chaluvadi et al. 2011)
Topiramate Increased breakthrough seizures with generic substitution Duh et al. (2009b)
Adverse effects with generics Pineyro-Lopez et al. (2009)
Gabapentin Increased breakthrough seizures with generic substitution Berg et al. (2008)
Phenobarbital Failure of drug therapy Bankstahl et al. (2013)
Oxcarbazepine Increased breakthrough seizures with generic substitution Cook et al. (2009)
Lamotrigine Increased breakthrough seizures with generic substitution Makus and McCormick (2007), Nielsen et al. (2008)
Toxicity and increased serum levels with generic substitution Srichaiya et al. (2008), Sabroe and Sabers (2008), Nielsen et al. (2008)
Adverse effects with generics Andermann et al. (2007), Makus and McCormick (2007)
Primidone Increased breakthrough seizures with generic substitution Wyllie et al. (1987)
Zonisamide Increased breakthrough seizures with generic substitution Berg et al. (2008)
Page 4 of 8Atif et al. SpringerPlus  (2016) 5:182 
carbamazepine and phenytoin respectively (Gidal and 
Tomson 2008).
According to the FDA, a drug is categorized as NTI if 
the minute changes in dose or blood concentration might 
cause dose and blood concentration dependent severe 
therapeutic failures or adverse drug reactions (Yu 2011). 
NTI indicates that small differences in the absorption of 
drugs may cause or lead to substantial negative impacts 
on health. NTI of AEDs compels the healthcare profes-
sionals to continuously monitor the plasma levels of 
these drugs.
According to the prescribers, there are certain drugs 
that pose problems upon generic substitution, such drugs 
can be described as NTI (Nuwer et  al. 1990). In gen-
eral, the therapeutic dose of almost all AEDs vary across 
patients. Therefore, it is highly recommended to indi-
vidualize the dose of AEDs based on the dose–response 
data of that particular patient (Crawford et al. 2006). This 
is applicable to almost all AEDs even wider therapeutic 
index and low toxicity profile drugs such as lamotrigine 
(Guberman and Corman 2000).
Wide ranging bioequivalence criteria
The best method to ensure therapeutic equivalency of 
pharmaceutical products is bioequivalence (BE). The bio-
equivalency of the generic products have been approved 
by the FDA since the enforcement of the Drug Price 
Competition and Patent term Restoration Act in 1984 
(Hatch–Waxman Amendments) (Karki 2005). According 
to the FDA, when two drugs are bioequivalent, it means 
that both of them will provide similar and desired clinical 
effects. Bioequivalence can be determined by maximum 
concentration of a drug in the plasma (Cmax) and the area 
under the plasma level-time curve up to the last quanti-
fiable concentration (AUCt) (Nightingale and Morrison 
1987; Henney 1999; Bialer and Midha 2010).
The criteria set by majority of the regulatory authori-
ties for two products to be bioequivalent is that the AUC 
and Cmax ratios of both the products should fall within a 
range of 80–125  % with 90  % confidence intervals (CI) 
(Chenu et al. 2009; FDA 2003). It would be beneficial to 
clearly specify the size of the CI for BE studies. As for 
practical purposes, generics of branded drugs have AUC 
and Cmax ratios that are very close to 1. With significant 
differences in either value, it would be unlikely for the CI 
to lie within the range of 80–125 % (Midha and McKay 
2009).
As far as two different generics of the same brand are 
concerned, there could be differences in their Cmax and 
AUC values. Such type of deviations are very significant 
for the medicinal products which have NTI, poor solu-
bility, excitatory or inhibitory effects on hepatic enzymes 
and/or those with non-linear pharmacokinetics (e.g. 
anticonvulsants) (Crawford et al. 2006; Borgheini 2003). 
Recently, two articles (using Monte Carlo methods) 
focused on the quantitative assessment of the generic 
AEDs, and used classic (80–125  %) and tighter (90–
111.11  %) BE limits. It was verified that generic AEDs 
should not be considered as therapeutically equivalent 
products (Karalis et al. 2013, 2014).
Table 2 Pharmacokinetics characteristics of AEDs which may increase the probability of problems associated with their 
generic substitution
AEDs Therapeutic range Pharmacokinetics parameters
Narrow therapeutic range Low water solubility Nonlinear pharmacokinetics
Carbamazepine 4–12 μg/ml Yes Yes Yes
Phenytoin 10–20 μg/ml Yes Yes Yes
Valproate 50–100 μg/ml Yes No Yes
Phenobarbital 20–40 μg/ml Yes No No
Ethosuximide 40–100 μg/ml Yes No Yes
Gabapentin 4–20 μg/ml Yes No Yes
Lamotrigine 4–20 μg/ml No Yes No
Levetiracetam 5–40 μg/ml Yes No No
Oxcarbazepine 10–40 μg/ml Yes Yes No
Topiramate 10–20 μg/ml Yes Yes No
Tiagibine 100–300 ng/ml Yes No No
Vigabatrin 0.8–36 μg/ml Yes No No
Primidone 5–10 μg/ml Yes Yes No
Felbamate 30–100 μg/ml Yes Yes No
Zonisamide 10–40 μg/ml Yes Yes Yes
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The approval of NTI generic products based on the 
BE parameters is highly controversial because appar-
ently there could be slight differences in the values but 
the effects could be diverse (Meredith 2003; Browne and 
Holmes 2001). Another important consideration in the 
context of generic substitution is the frequent change in 
the supply source of generic medicines which may com-
promise the condition of the patient (Meredith 2003). 
Change in the supply source of medicines is mainly due 
to availability of generic products at a lower cost. How-
ever, the complications arising from generic substitution 
of some medicines, for example AEDs, direct the physi-
cians and pharmacists to select the medicines based on 
brand names, specifically in high risk patient groups 
(Table  3). The published studies have already reported 
that many prescribers and physicians avoided and 
opposed the generic substitution of the AEDs because 
of a greater risk of breakthrough seizures (Perucca et al. 
2006; Jobst and Holmes 2004).
High‑risk patient groups
The problems caused by generic substitution of AEDs 
may particularly be significant in some specific groups of 
patients (Table 3). There are no systematic studies avail-
able regarding these high-risk groups, and there is little 
or no availability of any documented evidence that allow 
the quantification of the actual effect of these problems. 
However, physicians and pharmacists should remain alert 
to the problems and risks while substituting the generics. 
Patient-related information on their previous experiences 
of the generic substitution could also be beneficial to 
identify the risk-to-benefit ratio of generic substitution.
Examples of proposed risks to epileptic patients asso-
ciated with generic substitution of medicines include; 
limited availability of dosage forms, drug elimination 
problems in renal or hepatic compromised patients, 
etc. AEDs have pharmacokinetics interactions with oral 
contraceptives so these may cause problems when used 
concomitantly (Crawford 2002). Generic substitution of 
AEDs may cause an abrupt change in the plasma con-
centration of the drugs, and consequently there might be 
failure of contraceptive therapy (Tettenborn 2006).
Recommendations from the international societies
We have summarized the recommendations of various 
neurological societies in Table 4.
Limitations
Few AEDs for example, divalproex sodium and topira-
mate are also used as prophylactic agents for migraine 
(Chiossi et al. 2014; Steiner et al. 2007; Steiner 2005). But, 
due to the limited data available on the generic substitu-
tion of AEDs in migraine patients, and no such recom-
mendations from the headache organizations (American 
Academy of Neurology and American Headache Society), 
we mainly focused on the potential problems and recom-
mendations regarding generic substitution of AEDs in 
epilepsy patients.
Conclusion and recommendations
Generic substitution is preferred to reduce the healthcare 
costs. However, the available literature on epilepsy indi-
cate that substitution of AEDs is problematic, especially 
in certain patient groups. Generic-to-generic substitution 
is even not recommended based on the unavailability 
of BE data. Similarly, the wide-ranging criteria for bio-
equivalence permit variations in the drug exposure that 
might be clinically significant and require plasma level 
monitoring to avoid failure of drug therapy or incidence 
of adverse effects. Due to the potential risk of losing the 
control over seizures, various guidelines recommend 
that the well-controlled epileptic patients should avoid 
switching from brand-to-generic products, generic-to-
brand products and generic-to-generic products.
As few AEDs are also used for the prophylaxis of 
migraine we recommend that the researchers and the 
Table 3 Special categories of patients recommended for exclusion from the compulsory generic substitution (Lamy 1986; 
Krämer et al. 2007; Crawford et al. 2006)
Special categories Examples
High risk patients Extreme age groups, pregnant women, patients with multiple disorders being treated with several drugs, solitary individual, etc.
High risk diseases Chronic diseases, diseases aggravated after the administration of drugs prescribed for co-morbid condition, etc.
High risk drugs Narrow therapeutic index drugs, drugs requiring individualization of dose, drugs exhibiting severe drug–drug interactions, drugs 
with the complex therapeutic regimen, drugs initiating the prescribing cascade, etc.
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associated organizations should conduct similar stud-
ies in migraine patients to evaluate the potential ben-
efits and problems with generic substitution, and based 
on the results recommendations could be made for such 
patients.
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